Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum doublet chemotherapy with or without atorvastatin for first-line driver-negative advanced NSCLC
ChiCTR2100054406Phase 2Recruiting
- Sponsor
- Army Specialty Medical Center
- Start
- Jan 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin and tislelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Army Specialty Medical Center. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
atorvastatintislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100054406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054406.